Background Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death
before Omicron, but updated real-world evidence studies are needed. This study aimed to …

Objectives The aim of this analysis was to describe nirmatrelvir/ritonavir real-world
effectiveness in preventing hospitalization among high-risk US COVID-19 patients during …

Background In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …

Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …

Background The coronavirus disease 2019 (COVID-19) pandemic has caused significant
morbidity and mortality in high-risk populations. Several therapeutics have been developed …

Background Our objective was to evaluate the real world effectiveness of
nirmatrelvir/ritonavir to prevent severe COVID-19 while Omicron and its subvariants …

Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk
Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death …

Importance Postmarket analysis of individuals who receive nirmatrelvir and ritonavir
(Paxlovid [Pfizer]) is essential because they differ substantially from individuals included in …

ABSTRACT Background In the United States, oral nirmatrelvir-ritonavir (Paxlovid™) is
authorized for use among patients aged≥ 12 years with mild-to-moderate SARS-CoV-2 …

Background Studies have established the short-term efficacy of nirmatrelvir–ritonavir in
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …